Drug intelligence / Profile preview

IWR-1

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intratumoral

Overview

IWR-1 is a small molecule inhibitor that selectively inhibits Wnt/beta-catenin mediated signaling by inhibiting tankyrase1/2, thus stabilizing Axin and stimulating beta-catenin degradation. It is used as a research tool to study Wnt signaling pathways and has been shown to inhibit epithelial-mesenchymal transition, cell proliferation, migration, and invasion in cancer cell lines. IWR-1 is not approved for clinical use and is intended for research purposes only.

Other names: IWR-1-endoIWR1-endoIWR 1-endoendo-IWR 1endo-IWR1endo-IWR-14-(1,3,3a,4,7,7a-Hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-N-8-quinolinyl-Benzamide4-(3,5-Dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl)-N-quinolin-8-ylbenzamide

Targets

TNKS2 (Tankyrase 2)TNKS (Poly(ADP-ribose) Polymerase 5a)

Beyond the preview

Go deeper on IWR-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IWR-1.

Explore the full profile